View More Recent Stories
-
Insulet Corporation (PODD) PT Raised to $269 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $285 at Piper Sandler
-
Buy this MedTech stock: Jefferies
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Piper Sandler Reiterates Overweight Rating on Insulet Corporation (PODD)
-
Oppenheimer Reiterates Outperform Rating on Insulet Corporation (PODD)
-
Jefferies Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD): Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
-
Selloff in MedTech stocks 'seems overdone': Citi
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Use the pullback to buy pullback in this MedTech stock: JPMorgan
-
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
-
Insulet (PODD) Misses Q2 EPS by 1c, provides guidance
-
Insulet (PODD) preliminary Q2 revenue of $488 million, estimate $460.4 million
-
MedTech stocks: Q2 earnings season preview
-
Insulet (PODD) Announces Omnipod 5 Launch in France and U.S. Innovation Updates
-
3 MedTech stocks to own - Citi

